ABSTRACT
Parkinson’s disease is a complex and multifactorial disorder, but how its biological and clinical complexity emerge from molecular to macroscopic brain interactions remains poorly understood. Here, we use a personalized multiscale generative brain model to characterize direct spatiotemporal links between genes and multimodal neuroimaging-derived biological factors in PD. We identified a set of genes modulating PD-associated longitudinal changes in dopamine transporter level, neuronal activity, dendrite density and tissue atrophy. Inter-individual heterogeneity in the gene-mediated biological mechanisms is associated with five distinct configurations of PD motor and non-motor symptoms. Although characterized by distinctive biological pathways, all the symptom configurations are associated with cell cycle processes. Notably, the protein-protein interaction networks underlying these configurations revealed distinct hub genes including MYC, CCNA2, CCDK1, SRC, STAT3 and PSMD4. We also uncovered the biological mechanisms associated with physical activities performance in PD, and observed that leisure and work activities are principally related to neurotypical cholesterol homeostasis and inflammatory response processes, respectively. Finally, patient-tailored in silico gene perturbations revealed a set of putative disease-modifying drugs with potential to effectively treat PD, most of which are associated with dopamine reuptake and anti-inflammation. Our study constitutes the first self-contained multiscale approach providing comprehensive insights into the complex multifactorial pathogenesis of PD, unravelling key biological modulators of physical and clinical deterioration, and serving as a blueprint for optimum drug selection at personalized level.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was undertaken thanks in part to funding from: the Parkinson Canada and Fonds de recherche du Quebec Sante (FRQS) Graduate Partnership Fellowship awarded to QA, the Canada First Research Excellence Fund, awarded to McGill University for the Healthy Brains for Healthy Lives Initiative, the Canada Research Chair tier 2, Fonds de la recherche en sante du Quebec (FRQS) Junior 1 Scholarship, Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant, and Weston Brain Institute awards to YIM, the Brain Canada Foundation and Health Canada support to the McConnell Brain Imaging Center at the Montreal Neurological Institute, and the European Union Horizon 2020 Framework Programme for Research and Innovation under the Specific Grant Agreements 785907 (Human Brain Project SGA2) and 945539 (Human Brain Project SGA3) awarded to NPG and KZ. Multimodal imaging and clinical data collection and sharing for this project was funded by PPMI. A public-private partnership, PPMI is funded by the Michael J. Fox Foundation for Parkinson Research and funding partners, including AbbVie, Allergan, Amathus Therapeutics, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol Myers Squibb, Celgene, Denali Therapeutics, GE Healthcare, Genentech, GlaxoSmithKline plc., Golub Capital, Handl Therapeutics, Insitro, Janssen Neuroscience, Eli Lilly and Company, Lundbeck, Merck Sharp & Dohme Corp., Meso Scale Discovery, Neurocrine Biosciences, Pfizer Inc., Piramal Group, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier Laboratories, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB, Verily Life Sciences, and Voyager Therapeutics Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
PPMI (ppmi-info.org) AHBA (brain-map.org) HCP (humanconnectomeproject.org)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos